The first disease modifying therapies for Alzheimer’s may have limited utility in some senses, but they will be a force for change, providing momentum and altering the way governments as payers, and health systems as carers, think about the disease. Read More
Researchers from ADT Pharmaceuticals and affiliated organizations have published preclinical data for the pan-RAS inhibitor ADT-007, being developed as an anticancer agent. Read More
Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform to be broadly effective against viruses of the paramyxoviridae family have also shown promising in silico activity against measles and Nipah viruses. The candidates were previously shown to be active in vitro against respiratory syncytial virus and human parainfluenza virus 3. Read More
Epicrispr Biotechnologies Inc. has secured $68 million in the first close of its series B financing to support the clinical development of EPI-321, a first-in-class epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). Read More
Precision Biosciences Inc. recently presented a new gene-editing approach, PBGENE-DMD, which could allow life-long benefits to patients with Duchenne muscular dystrophy (DMD). Read More
Tribune Therapeutics AB has raised €37 million (US$40 million) in seed and series A funding to advance a portfolio of therapies targeting central drivers of scar tissue formation. Read More
Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders. Read More
The endocannabinoid system is an endogenous neuromodulatory system that is highly expressed in the central nervous system (CNS) and peripheral tissues and is known to play an important role in modulating learning and memory processes, where the cannabinoid CB1 receptor is the most widely expressed G protein-coupled receptor in the CNS, although its presence is also high in peripheral tissues. Read More
rietis Corp. and St. Jude Children’s Research Hospital Inc. have jointly patented compounds acting as caseinolytic protease P (ClpP) (bacterial) activators and RNA polymerase (bacterial) inhibitors and their conjugates with rifamycin analogues reported to be useful for the treatment of gram-positive bacterial infection. Read More
GTPase KRAS G12D mutant and/or G12V mutant inhibitors potentially useful for the treatment of cancer have been detailed in a Quanta Therapeutics Inc. Read More
Researchers from Chinese Academy of Sciences detailed the creation of a new dextran sulfate sodium (DSS)-based mouse model of immune checkpoint blockade (ICB) therapy-associated colitis. Read More
Work at Purdue Research Foundation has led to the identification of prodrugs of nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of cancer. Read More
Maze Therapeutics Inc. has disclosed new sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, hyperphenylalaninemia, tyrosinemia, isovaleric acidemia, propionic acidemia, maple syrup urine disease and chronic kidney disease, among others. Read More
In a recently published study, researchers from the International Centre for Genetic Engineering and Biotechnology in Italy used data from a previous high-throughput screening using human miRNA mimics and selected miR-148a-3p as a therapeutic target. Read More
